National Quality Forum, Washington, DC; The University of Texas MD Anderson Cancer Center, Houston, TX; Stanford University, Stanford, CA; Seoul National University, Seoul, South Korea; Baylor College of Medicine, Houston, TX; Deloitte Consulting, Dallas, TX; UnitedHealthcare, Minnetonka, MN; and Harvard Business School, Cambridge, MA.
J Oncol Pract. 2018 Feb;14(2):e103-e112. doi: 10.1200/JOP.2017.027029. Epub 2017 Dec 22.
Despite growing interest in bundled payments to reduce the costs of care, this payment method remains largely untested in cancer. This 3-year pilot tested the feasibility of a 1-year bundled payment for the multidisciplinary treatment of head and neck cancers.
Four prospective treatment-based bundles were developed for patients with selected head and neck cancers. These risk-adjusted bundles covered 1 year of care that began with primary cancer treatment. Manual processes were developed for patient identification, enrollment, billing, and payment. Patients were prospectively identified and enrolled, and bundled payments were made at treatment start. Operational metrics tracked incremental effort for pilot processes and average payment cycle time compared with fee-for-service (FFS) payments.
This pilot confirmed the feasibility of a 1-year prospective bundled payment for head and neck cancers. Between November 2014 and October 2016, 88 patients were enrolled successfully with prospective bundled payments. Through September 2017, 94% of patients completed the pilot with 6% still enrolled. Manual pilot processes required more effort than anticipated; claims processing was the most time-consuming activity. The production of a bundle bill took an additional 15 minutes versus FFS billing. The average payment cycle time was 37 days (range, 15 to 141 days) compared with a 15-day average under FFS.
Prospective bundled payments were successfully implemented in this pilot. Additional pilots should study this payment method in higher-volume cancers. Robust systems are needed to automate patient identification, enrollment, billing, and payment along with policies that reduce administrative burden and allow for the introduction of novel cancer therapies.
尽管人们对捆绑式支付以降低医疗成本越来越感兴趣,但这种支付方式在癌症治疗中仍基本未经检验。这项为期 3 年的试点研究测试了对多种学科治疗头颈部癌症进行为期 1 年的捆绑式支付的可行性。
为选定的头颈部癌症患者制定了 4 个基于治疗的前瞻性捆绑包。这些风险调整后的捆绑包涵盖了从原发性癌症治疗开始的 1 年的护理。为患者识别、登记、计费和支付制定了手工流程。对患者进行前瞻性识别和登记,并在治疗开始时支付捆绑式付款。运营指标跟踪试点流程的增量工作以及与按服务收费(FFS)付款相比的平均付款周期时间。
该试点证实了对头颈部癌症进行为期 1 年的前瞻性捆绑式支付的可行性。2014 年 11 月至 2016 年 10 月期间,成功为 88 名患者进行了前瞻性捆绑式付款登记。截至 2017 年 9 月,94%的患者完成了试点,仍有 6%的患者在登记中。手动试点流程比预期需要更多的努力;理赔处理是最耗时的活动。与 FFS 计费相比,编制捆绑账单需要额外 15 分钟。平均付款周期时间为 37 天(范围为 15 至 141 天),而 FFS 的平均付款周期时间为 15 天。
前瞻性捆绑式支付在该试点中成功实施。应在更高容量的癌症中进行更多的试点研究来研究这种支付方式。需要建立强大的系统,以便自动进行患者识别、登记、计费和支付,同时制定政策以减轻行政负担并允许引入新型癌症疗法。